

# Executive Branch Personnel

## Public Financial Disclosure Report:

### Periodic Transaction Report (OGE Form 278-T)

#### Filer's Information

---

Fink, Dorothy A

Deputy Assistant Secretary for Women's Health, Department of Health & Human Services

---

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Fink, Dorothy A [electronically signed on 03/19/2019 by Fink, Dorothy A in Integrity.gov]

---

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Trent-Adams, Sylvia, Certifying Official [electronically signed on 05/13/2019 by Trent-Adams, Sylvia in Integrity.gov]

---

Other review conducted by

/s/ McClure, Chester, Ethics Official [electronically signed on 05/10/2019 by McClure, Chester in Integrity.gov]

---

U.S. Office of Government Ethics Certification

---

Data Revised 05/10/2019

## Comments of Reviewing Officials (public annotations):

PART	#	REFERENCE	COMMENT
N/A	N/A	General	<p>(05/10/2019, McClure, Chester): Initial Review 3/27/19. Dr. Fink initially became federal employee upon appointment to her new position on December 10, 2018. All of the sales on this report completed to comply with a formal ethics agreement drafted by HHS General Counsel's Ethics Division. The agreement required divestiture of these assets within 90-days of her appointment (by March 10, 2019). Filer has fully complied with the ethics agreement. No ethics concerns.</p> <p>Dr. Fink was delayed in submitting this Transaction Report due to network access issues upon joining HHS. Thus no concerns about timeliness of filing. Edits made per filer guidance and confirmed upon resubmission.</p>

## Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	General Electric Co, Common stock	Sale	12/26/2018	No	\$1,001 - \$15,000
2	Abbott Laboratories, Common stock	Sale	02/06/2019	No	\$15,001 - \$50,000
3	General Electric Co, Common stock	Sale	02/12/2019	No	\$1,001 - \$15,000
4	Glaxosmithkline, Common stock	Sale	02/06/2019	No	\$1,001 - \$15,000
5	Tandem Diabetes Care, Inc. - Common Stock	Sale	02/08/2019	No	\$1,001 - \$15,000
6	L Brands Inc, Common stock	Sale	02/11/2019	No	\$1,001 - \$15,000
7	Kraft Heinz Co., Common stock	Sale	02/12/2019	No	\$1,001 - \$15,000

## Endnotes

## Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

### Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to another Federal agency, court or party in a court or Federal administrative proceeding when the Government is a party or in order to comply with a judge-issued subpoena; (4) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (5) to the National Archives and Records Administration or the General Services Administration in records management inspections; (6) to the Office of Management and Budget during legislative coordination on private relief legislation; (7) to the Department of Justice or in certain legal proceedings when the disclosing agency, an employee of the disclosing agency, or the United States is a party to litigation or has an interest in the litigation and the use of such records is deemed relevant and necessary to the litigation; (8) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another; (9) to a Member of Congress or a congressional office in response to an inquiry made on behalf of an individual who is the subject of the record; (10) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to an OGE Government-wide system of records; and (11) on the OGE Website and to any person, department or agency, any written ethics agreement filed with OGE by an individual nominated by the President to a position requiring Senate confirmation. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.

---